News
REGN
1060.86
+0.50%
5.29
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Seeking Alpha · 1d ago
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Dow Jones · 1d ago
Regeneron Pharma Is Maintained at Buy by TD Cowen
Dow Jones · 1d ago
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1200
Benzinga · 1d ago
Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Seeking Alpha · 2d ago
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology announces treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron's cemiplimab. Six patients remain on treatment following at least 12 months of treatment. In June, MAIA shared new efficacy data from the study.
Benzinga · 2d ago
REGENERON PHARMACEUTICALS INC <REGN.O>: TD COWEN RAISES TARGET PRICE TO $1,200 FROM $1,030
Reuters · 2d ago
TD Cowen Keeps Their Buy Rating on Regeneron (REGN)
TipRanks · 2d ago
Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN)
TipRanks · 2d ago
BBH: Buy Rating, As Tech Investors Look Beyond FAANG
VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. The VanEck biotech ETF (BBH) is under-discovered compared to peers, offers potential for trend change in biotech sector.
Seeking Alpha · 2d ago
U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Colgate-Palmolive, McKesson, Microsoft and Air Products & Chemicals among those. AIG, AIG and others have seen their target prices cut by some analysts.
Reuters · 2d ago
Court weighs what US must prove in Regeneron kickback case
U.S. Department of Justice wants appeals court to overturn judge's ruling in kickback case against drugmaker. The Justice Department accused Regeneron Pharmaceuticals of using a charity to pay kickbacks to pay for drugs. The drugmaker denies the allegations. The government says the ruling makes it harder to hold companies accountable for paying kickbacks.
Reuters · 2d ago
Regeneron Pharma Price Target Raised to $1000.00/Share From $925.00 by Cantor Fitzgerald
Dow Jones · 3d ago
Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
Dow Jones · 3d ago
REGENERON PHARMACEUTICALS INC <REGN.O>: JEFFERIES RAISES TARGET PRICE TO $1,235 FROM $1,135
Reuters · 3d ago
Weekly Report: what happened at REGN last week (0715-0719)?
Weekly Report · 3d ago
U.S. RESEARCH ROUNDUP-Align Technology, McKesson, Schneider National
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Align Technology, McKesson, and Schneider National have lower targets. Abercrombie & Fitch, American Airlines and Amazon.com among the companies with new targets cut.
Reuters · 3d ago
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's short percent of float has risen 10.17% since its last report. The company has 2.04 million shares sold short, which is 1.95% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 6d ago
Why Novartis Deserves Your Attention After Q2 2024 Results
Seeking Alpha · 6d ago
Regeneron Pharma Is Maintained at Overweight by Piper Sandler
Dow Jones · 6d ago
More
Webull provides a variety of real-time REGN stock news. You can receive the latest news about Regeneron Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.